NCT04221464 Development of a Clinical and Biological Database in Peritoneal Carcinosis (BCB CARCINOSE)
| NCT ID | NCT04221464 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institut du Cancer de Montpellier - Val d'Aurelle |
| Condition | Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 600 participants |
| Start Date | 2019-11-25 |
| Primary Completion | 2028-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 600 participants in total. It began in 2019-11-25 with a primary completion date of 2028-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The creation of a prospective clinical-biological base dedicated to peritoneal carcinosis must therefore be able to serve as a support for this essential search for transfer.
Eligibility Criteria
Inclusion Criteria: * Patient over the age of 18; * Patient managed for peritoneal carcinosis : digestives origins (pancreatic, gastroesophageal junction, colorectal, bowel) or peritoneum cancer * Patient eligible for a peritoneal carcinosis treatment : at least one (or more) surgery (s) ;chemotherapy or any treatment for this disease * Patient agree will all study procedure : biological samples \& tissues samples * Patient giving informed consent Exclusion Criteria: * Patient not affiliated to Social Protection system * Patient unable to understand or comply with study instructions or requirements for psychological, family, social or geographical reasons * The level of French is insufficient to consent to the study and to response to the questionnaires * Patient under guardianship * Pregnancy ou breast-feeding women * Patient treated in case of an emergency
Contact & Investigator
François QUENET,MD
STUDY CHAIR
Institut régional du cancer de Montpellier
Frequently Asked Questions
Who can join the NCT04221464 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04221464 currently recruiting?
Yes, NCT04221464 is actively recruiting participants. Contact the research team at aurore.moussion@icm.unicancer.fr for enrollment information.
Where is the NCT04221464 trial being conducted?
This trial is being conducted at Montpellier, France.
Who is sponsoring the NCT04221464 clinical trial?
NCT04221464 is sponsored by Institut du Cancer de Montpellier - Val d'Aurelle. The principal investigator is François QUENET,MD at Institut régional du cancer de Montpellier. The trial plans to enroll 600 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.